Chembio Diagnostics (CEMI) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Chembio Diagnostics (NASDAQ:CEMI) issued its quarterly earnings data on Thursday. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.10), Fidelity Earnings reports. The firm had revenue of $9.38 million for the quarter. Chembio Diagnostics had a negative net margin of 16.54% and a negative return on equity of 26.91%.

Shares of NASDAQ:CEMI traded down $0.47 during midday trading on Friday, hitting $6.78. 727,980 shares of the stock traded hands, compared to its average volume of 126,979. The company has a market cap of $103.83 million, a price-to-earnings ratio of -13.04 and a beta of 1.46. The company has a current ratio of 3.53, a quick ratio of 2.58 and a debt-to-equity ratio of 0.02. Chembio Diagnostics has a one year low of $6.44 and a one year high of $11.55.

In other news, insider Robert Passas acquired 15,000 shares of the stock in a transaction dated Monday, November 5th. The stock was purchased at an average cost of $6.75 per share, with a total value of $101,250.00. Following the completion of the purchase, the insider now owns 15,000 shares in the company, valued at approximately $101,250. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 4.65% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Chembio Diagnostics (CEMI) Releases Quarterly Earnings Results, Misses Estimates By $0.10 EPS” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at

About Chembio Diagnostics

Chembio Diagnostics, Inc, together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi.

Read More: Analyst Ratings

Earnings History for Chembio Diagnostics (NASDAQ:CEMI)

Receive News & Ratings for Chembio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chembio Diagnostics and related companies with's FREE daily email newsletter.

Leave a Reply